Sensitivity analysis. Three-way sensitivity analysis varying the cost of carfilzomib, withdrawal rate from second-line treatment, and (A) rate of MRD-negativity with D-RVd, transition probability to calculate PFS of (B) DKd and (C) Kd, and (D) cost of daratumumab. Two withdrawal rates, 0.06 (base case) and 0.25 (25% of the patients withdraw from treatment without receiving second-line), were analyzed. Blue and red areas indicate that D-RVd and RVd are cost-effective within those values, respectively. Dashed black lines indicate the base case or other clinically important values.